Description: Erlotinib D6 (CP358774 D6; NSC718781 D6; OSI774 D6) is a deuterated form of Erlotinib (CP-358774). Erlotinib
(also known as OSI-744, trade name: Tarceva) is an EGFR (epidermal
growth factor receptor) inhibitor with IC50 of 2 nM in cell-free assays,
and is 1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib
is a quinazoline derivative with potent antineoplastic properties and
has been approved for the treatment of non-small cell lung cancer
(NSCLC), pancreatic cancer and several other types of cancer.
References:Induction
of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of
epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997,
57(21), 4838-4848.